Progenics Finds New Partner For Relistor In Salix

A casualty of the Pfizer/Wyeth merger, Relistor rights bring Progenics $60 million upfront plus up to $290 million in milestones plus royalties.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet